{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T01:21:51Z","timestamp":1790990511260,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    With the increasing prevalence of artemisinin-resistant malaria parasites, a highly efficacious and durable vaccine for malaria is urgently required. We have developed an experimental virus-vectored vaccine platform based on an envelope-modified baculovirus dual-expression system (emBDES). Here, we show a conceptually new vaccine platform based on an adenovirus-prime\/emBDES-boost heterologous immunization regimen expressing the\n                    <jats:italic>Plasmodium falciparum<\/jats:italic>\n                    circumsporozoite protein (PfCSP). A human adenovirus 5-prime\/emBDES-boost heterologous immunization regimen consistently achieved higher sterile protection against transgenic\n                    <jats:italic>P. berghei<\/jats:italic>\n                    sporozoites expressing PfCSP after a mosquito-bite challenge than reverse-ordered or homologous immunization. This high protective efficacy was also achieved with a chimpanzee adenovirus 63-prime\/emBDES-boost heterologous immunization regimen against an intravenous sporozoite challenge. Thus, we show that the adenovirus-prime\/emBDES-boost heterologous immunization regimen confers sterile protection against sporozoite challenge by two individual routes, providing a promising new malaria vaccine platform for future clinical use.\n                  <\/jats:p>","DOI":"10.1038\/s41598-018-21369-y","type":"journal-article","created":{"date-parts":[[2018,2,23]],"date-time":"2018-02-23T10:32:02Z","timestamp":1519381922000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Adenovirus-prime and baculovirus-boost heterologous immunization achieves sterile protection against malaria sporozoite challenge in a murine model"],"prefix":"10.1038","volume":"8","author":[{"given":"Kunitaka","family":"Yoshida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Iyori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Blagborough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9259-7339","authenticated-orcid":false,"given":"Ahmed M.","family":"Salman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawan","family":"Dulal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna A.","family":"Sala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4347-7808","authenticated-orcid":false,"given":"Daisuke S.","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahid M.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris J.","family":"Janse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumi","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Yoshii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yenni","family":"Yusuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaharu","family":"Tokoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0900-9629","authenticated-orcid":false,"given":"Adrian V. S.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeto","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,1]]},"reference":[{"key":"21369_CR1","unstructured":"WHO. World malaria report 2017. World Health Organization, Geneva, Switzerland, http:\/\/www.who.int\/malaria\/publications\/world-malaria-report-2017\/en\/ (2017)."},{"key":"21369_CR2","doi-asserted-by":"publisher","first-page":"e1001685","DOI":"10.1371\/journal.pmed.1001685","volume":"11","author":"PA Minsoko","year":"2014","unstructured":"Minsoko, P. A. et al. Efficacy and Safety of the RTS,S\/AS01 Malaria Vaccine during 18 Months after Vaccination: A Phase 3 Randomized, Controlled Trial in Children and Young Infants at 11 African Sites. PloS Med 11, e1001685 (2014).","journal-title":"PloS Med"},{"key":"21369_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","volume":"386","author":"H Tinto","year":"2015","unstructured":"Tinto, H. et al. Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 386, 31\u201345 (2015).","journal-title":"Lancet"},{"key":"21369_CR4","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1016\/S1473-3099(15)00239-X","volume":"15","author":"MT White","year":"2015","unstructured":"White, M. T. et al. Immunogenicity of the RTS,S\/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial. Lancet Infect Dis 15, 1450\u20131458 (2015).","journal-title":"Lancet Infect Dis"},{"key":"21369_CR5","doi-asserted-by":"publisher","first-page":"e61395","DOI":"10.1371\/journal.pone.0061395","volume":"8","author":"MT White","year":"2013","unstructured":"White, M. T. et al. The relationship between RTS,S vaccine-induced antibodies, CD4(+) T cell responses and protection against Plasmodium falciparum infection. PLoS One 8, e61395 (2013).","journal-title":"PLoS One"},{"key":"21369_CR6","doi-asserted-by":"publisher","first-page":"e0131571","DOI":"10.1371\/journal.pone.0131571","volume":"10","author":"CF Ockenhouse","year":"2015","unstructured":"Ockenhouse, C. F. et al. Ad35.CS.01 - RTS,S\/AS01 heterologous prime boost vaccine efficacy against sporozoite challenge in healthy malaria-naive adults. PLoS One 10, e0131571 (2015).","journal-title":"PLoS One"},{"key":"21369_CR7","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1073\/pnas.1621489114","volume":"114","author":"D Kazmin","year":"2017","unstructured":"Kazmin, D. et al. Systems analysis of protective immune responses to RTS,S malaria vaccination in humans. Proc Natl Acad Sci USA 114, 2425\u20132430 (2017).","journal-title":"Proc Natl Acad Sci USA"},{"key":"21369_CR8","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1128\/IAI.01226-08","volume":"77","author":"S Yoshida","year":"2009","unstructured":"Yoshida, S., Kawasaki, M., Hariguchi, N., Hirota, K. & Matsumoto, M. A baculovirus dual expression system-based malaria vaccine induces strong protection against Plasmodium berghei sporozoite challenge in mice. Infect Immun 77, 1782\u20131789 (2009).","journal-title":"Infect Immun"},{"key":"21369_CR9","doi-asserted-by":"publisher","first-page":"4348","DOI":"10.1128\/IAI.02040-14","volume":"82","author":"M Mizutani","year":"2014","unstructured":"Mizutani, M. et al. Baculovirus-vectored multistage Plasmodium vivax vaccine induces both protective and transmission-blocking immunities against transgenic rodent malaria parasites. Infect Immun 82, 4348\u20134357 (2014).","journal-title":"Infect Immun"},{"key":"21369_CR10","doi-asserted-by":"publisher","first-page":"e70819","DOI":"10.1371\/journal.pone.0070819","volume":"8","author":"M Iyori","year":"2013","unstructured":"Iyori, M. et al. Protective efficacy of baculovirus dual expression system vaccine expressing Plasmodium falciparum circumsporozoite protein. PLoS One 8, e70819 (2013).","journal-title":"PLoS One"},{"key":"21369_CR11","doi-asserted-by":"publisher","first-page":"e13727","DOI":"10.1371\/journal.pone.0013727","volume":"5","author":"S Yoshida","year":"2010","unstructured":"Yoshida, S. et al. Plasmodium berghei circumvents immune responses induced by merozoite surface protein 1- and apical membrane antigen 1-based vaccines. PLoS One 5, e13727 (2010).","journal-title":"PLoS One"},{"key":"21369_CR12","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1128\/IAI.00877-09","volume":"78","author":"S Yoshida","year":"2010","unstructured":"Yoshida, S., Araki, H. & Yokomine, T. Baculovirus-based nasal drop vaccine confers complete protection against malaria by natural boosting of vaccine-induced antibodies in mice. Infect Immun 78, 595\u2013602 (2010).","journal-title":"Infect Immun"},{"key":"21369_CR13","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.vaccine.2014.11.038","volume":"33","author":"KA Sala","year":"2015","unstructured":"Sala, K. A. et al. The Plasmodium berghei sexual stage antigen PSOP12 induces anti-malarial transmission blocking immunity both in vivo and in vitro. Vaccine 33, 437\u2013445 (2015).","journal-title":"Vaccine"},{"key":"21369_CR14","doi-asserted-by":"publisher","first-page":"6014","DOI":"10.1016\/j.vaccine.2010.06.100","volume":"28","author":"AM Blagborough","year":"2010","unstructured":"Blagborough, A. M., Yoshida, S., Sattabongkot, J., Tsuboi, T. & Sinden, R. E. Intranasal and intramuscular immunization with Baculovirus Dual Expression System-based Pvs25 vaccine substantially blocks Plasmodium vivax transmission. Vaccine 28, 6014\u20136020 (2010).","journal-title":"Vaccine"},{"key":"21369_CR15","doi-asserted-by":"publisher","first-page":"7025","DOI":"10.1016\/j.vaccine.2010.08.022","volume":"28","author":"G Mlambo","year":"2010","unstructured":"Mlambo, G., Kumar, N. & Yoshida, S. Functional immunogenicity of baculovirus expressing Pfs25, a human malaria transmission-blocking vaccine candidate antigen. Vaccine 28, 7025\u20137029 (2010).","journal-title":"Vaccine"},{"key":"21369_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-017-2039-x","volume":"16","author":"M Iyori","year":"2017","unstructured":"Iyori, M. et al. DAF-shielded baculovirus-vectored vaccine enhances protection against malaria sporozoite challenge in mice. Malar J 16, 390 (2017).","journal-title":"Malar J"},{"key":"21369_CR17","doi-asserted-by":"crossref","unstructured":"Iyori, M. et al. Protective efficacy of an IL-12-expressing baculoviral malaria vaccine. Parasite Immunol\u00a039 (2017).","DOI":"10.1111\/pim.12498"},{"key":"21369_CR18","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1128\/IAI.69.2.681-686.2001","volume":"69","author":"H McShane","year":"2001","unstructured":"McShane, H., Brookes, R., Gilbert, S. C. & Hill, A. V. Enhanced immunogenicity of CD4(\u2009+\u2009) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. Infect Immun 69, 681\u2013686 (2001).","journal-title":"Infect Immun"},{"key":"21369_CR19","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1128\/IAI.69.4.2714-2717.2001","volume":"69","author":"JV Brooks","year":"2001","unstructured":"Brooks, J. V., Frank, A. A., Keen, M. A., Bellisle, J. T. & Orme, I. M. Boosting vaccine for tuberculosis. Infect Immun 69, 2714\u20132717 (2001).","journal-title":"Infect Immun"},{"key":"21369_CR20","doi-asserted-by":"publisher","first-page":"4634","DOI":"10.1128\/IAI.00517-06","volume":"74","author":"M Santosuosso","year":"2006","unstructured":"Santosuosso, M., McCormick, S., Zhang, X., Zganiacz, A. & Xing, Z. Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis. Infect Immun 74, 4634\u20134643 (2006).","journal-title":"Infect Immun"},{"key":"21369_CR21","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/j.vaccine.2013.11.045","volume":"32","author":"G Dean","year":"2014","unstructured":"Dean, G. et al. Comparison of the immunogenicity and protection against bovine tuberculosis following immunization by BCG-priming and boosting with adenovirus or protein based vaccines. Vaccine 32, 1304\u20131310 (2014).","journal-title":"Vaccine"},{"key":"21369_CR22","doi-asserted-by":"publisher","first-page":"e5856","DOI":"10.1371\/journal.pone.0005856","volume":"4","author":"Z Xing","year":"2009","unstructured":"Xing, Z. et al. Intranasal mucosal boosting with an adenovirus-vectored vaccine markedly enhances the protection of BCG-primed guinea pigs against pulmonary tuberculosis. PLoS One 4, e5856 (2009).","journal-title":"PLoS One"},{"key":"21369_CR23","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1038\/mt.2008.59","volume":"16","author":"EK Roediger","year":"2008","unstructured":"Roediger, E. K., Kugathasan, K., Zhang, X., Lichty, B. D. & Xing, Z. Heterologous boosting of recombinant adenoviral prime immunization with a novel vesicular stomatitis virus-vectored tuberculosis vaccine. Mol Ther 16, 1161\u20131169 (2008).","journal-title":"Mol Ther"},{"key":"21369_CR24","doi-asserted-by":"publisher","first-page":"9710","DOI":"10.1128\/JVI.77.17.9710-9715.2003","volume":"77","author":"A Takeda","year":"2003","unstructured":"Takeda, A. et al. Protective efficacy of an AIDS vaccine, a single DNA priming followed by a single booster with a recombinant replication-defective Sendai virus vector, in a macaque AIDS model. J Virol 77, 9710\u20139715 (2003).","journal-title":"J Virol"},{"key":"21369_CR25","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.1016\/j.vaccine.2006.03.045","volume":"24","author":"N Matoba","year":"2006","unstructured":"Matoba, N. et al. Humoral immune responses by prime-boost heterologous route immunizations with CTB-MPR(649-684), a mucosal subunit HIV\/AIDS vaccine candidate. Vaccine 24, 5047\u20135055 (2006).","journal-title":"Vaccine"},{"key":"21369_CR26","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/nature01876","volume":"424","author":"NJ Sullivan","year":"2003","unstructured":"Sullivan, N. J. et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 424, 681\u2013684 (2003).","journal-title":"Nature"},{"key":"21369_CR27","doi-asserted-by":"publisher","first-page":"e0118881","DOI":"10.1371\/journal.pone.0118881","volume":"10","author":"KL Warfield","year":"2015","unstructured":"Warfield, K. L. et al. Homologous and heterologous protection of nonhuman primates by Ebola and Sudan virus-like particles. PLoS One 10, e0118881 (2015).","journal-title":"PLoS One"},{"key":"21369_CR28","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1128\/IAI.00740-09","volume":"78","author":"A Reyes-Sandoval","year":"2010","unstructured":"Reyes-Sandoval, A. et al. Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses. Infect Immun 78, 145\u2013153 (2010).","journal-title":"Infect Immun"},{"key":"21369_CR29","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.vaccine.2010.10.041","volume":"29","author":"S Capone","year":"2010","unstructured":"Capone, S. et al. Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates. Vaccine 29, 256\u2013265 (2010).","journal-title":"Vaccine"},{"key":"21369_CR30","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1128\/IAI.01187-13","volume":"82","author":"K Bauza","year":"2014","unstructured":"Bauza, K. et al. Efficacy of a Plasmodium vivax malaria vaccine using ChAd63 and modified vaccinia Ankara expressing thrombospondin-related anonymous protein as assessed with transgenic Plasmodium berghei parasites. Infect Immun 82, 1277\u20131286 (2014).","journal-title":"Infect Immun"},{"key":"21369_CR31","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.coi.2016.06.008","volume":"42","author":"N Van Braeckel-Budimir","year":"2016","unstructured":"Van Braeckel-Budimir, N., Kurup, S. P. & Harty, J. T. Regulatory issues in immunity to liver and blood-stage malaria. Curr Opin Immunol 42, 91\u201397 (2016).","journal-title":"Curr Opin Immunol"},{"key":"21369_CR32","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.4049\/jimmunol.1100302","volume":"187","author":"A Reyes-Sandoval","year":"2011","unstructured":"Reyes-Sandoval, A. et al. CD8+ T effector memory cells protect against liver-stage malaria. J Immunol 187, 1347\u20131357 (2011).","journal-title":"J Immunol"},{"key":"21369_CR33","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/j.1600-065X.2008.00671.x","volume":"225","author":"MG Overstreet","year":"2008","unstructured":"Overstreet, M. G., Cockburn, I. A., Chen, Y. C. & Zavala, F. Protective CD8 T cells against Plasmodium liver stages: immunobiology of an \u2018unnatural\u2019 immune response. Immunol Rev 225, 272\u2013283 (2008).","journal-title":"Immunol Rev"},{"key":"21369_CR34","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1126\/science.1211548","volume":"334","author":"JE Epstein","year":"2011","unstructured":"Epstein, J. E. et al. Live attenuated malaria vaccine designed to protect through hepatic CD8 T cell immunity. Science 334, 475\u2013480 (2011).","journal-title":"Science"},{"key":"21369_CR35","doi-asserted-by":"publisher","first-page":"e1000998","DOI":"10.1371\/journal.ppat.1000998","volume":"6","author":"NW Schmidt","year":"2010","unstructured":"Schmidt, N. W., Butler, N. S., Badovinac, V. P. & Harty, J. T. Extreme CD8 T cell requirements for anti-malarial liver-stage immunity following immunization with radiation attenuated sporozoites. PLoS Pathog 6, e1000998 (2010).","journal-title":"PLoS Pathog"},{"key":"21369_CR36","first-page":"351","volume":"11","author":"E Nwanegbo","year":"2004","unstructured":"Nwanegbo, E. et al. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin Diagn Lab Immunol 11, 351\u2013357 (2004).","journal-title":"Clin Diagn Lab Immunol"},{"key":"21369_CR37","doi-asserted-by":"publisher","first-page":"e40385","DOI":"10.1371\/journal.pone.0040385","volume":"7","author":"MD Dicks","year":"2012","unstructured":"Dicks, M. D. et al. A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. PLoS One 7, e40385 (2012).","journal-title":"PLoS One"},{"key":"21369_CR38","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1128\/CVI.00723-13","volume":"21","author":"I Nebie","year":"2014","unstructured":"Nebie, I. et al. Assessment of chimpanzee adenovirus serotype 63 neutralizing antibodies prior to evaluation of a candidate malaria vaccine regimen based on viral vectors. Clin Vaccine Immunol 21, 901\u2013903 (2014).","journal-title":"Clin Vaccine Immunol"},{"key":"21369_CR39","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S0022-1759(03)00265-5","volume":"281","author":"MR Betts","year":"2003","unstructured":"Betts, M. R. et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 281, 65\u201378 (2003).","journal-title":"J Immunol Methods"},{"key":"21369_CR40","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jim.2004.08.008","volume":"294","author":"G Alter","year":"2004","unstructured":"Alter, G., Malenfant, J. M. & Altfeld, M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods 294, 15\u201322 (2004).","journal-title":"J Immunol Methods"},{"key":"21369_CR41","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1093\/infdis\/jiu579","volume":"211","author":"SH Hodgson","year":"2015","unstructured":"Hodgson, S. H. et al. Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals. J Infect Dis 211, 1076\u20131086 (2015).","journal-title":"J Infect Dis"},{"key":"21369_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/srep11820","volume":"5","author":"RJ Longley","year":"2015","unstructured":"Longley, R. J. et al. Comparative assessment of vaccine vectors encoding ten malaria antigens identifies two protective liver-stage candidates. Scientific reports 5, 11820 (2015).","journal-title":"Scientific reports"},{"key":"21369_CR43","doi-asserted-by":"publisher","first-page":"4965","DOI":"10.1128\/JVI.03510-12","volume":"87","author":"WY Luo","year":"2013","unstructured":"Luo, W. Y. et al. Adaptive immune responses elicited by baculovirus and impacts on subsequent transgene expression in vivo. J Virol 87, 4965\u20134973 (2013).","journal-title":"J Virol"},{"key":"21369_CR44","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.chroma.2013.03.047","volume":"1290","author":"P Gerster","year":"2013","unstructured":"Gerster, P. et al. Purification of infective baculoviruses by monoliths. Journal of chromatography. A 1290, 36\u201345 (2013).","journal-title":"Journal of chromatography. A"},{"key":"21369_CR45","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nm1592","volume":"13","author":"PA Darrah","year":"2007","unstructured":"Darrah, P. A. et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 13, 843\u2013850 (2007).","journal-title":"Nat Med"},{"key":"21369_CR46","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nri2274","volume":"8","author":"RA Seder","year":"2008","unstructured":"Seder, R. A., Darrah, P. A. & Roederer, M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 8, 247\u2013258 (2008).","journal-title":"Nat Rev Immunol"},{"key":"21369_CR47","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1084\/jem.20012024","volume":"195","author":"S Azeredo da Silveira","year":"2002","unstructured":"Azeredo da Silveira, S. et al. Complement activation selectively potentiates the pathogenicity of the IgG2b and IgG3 isotypes of a high affinity anti-erythrocyte autoantibody. J Exp Med 195, 665\u2013672 (2002).","journal-title":"J Exp Med"},{"key":"21369_CR48","doi-asserted-by":"crossref","first-page":"222","DOI":"10.4269\/ajtmh.2005.73.222","volume":"73","author":"CC John","year":"2005","unstructured":"John, C. C. et al. Correlation of high levels of antibodies to multiple pre-erythrocytic Plasmodium falciparum antigens and protection from infection. Am J Trop Med Hyg 73, 222\u2013228 (2005).","journal-title":"Am J Trop Med Hyg"},{"key":"21369_CR49","doi-asserted-by":"publisher","first-page":"3622","DOI":"10.1016\/j.vaccine.2004.03.029","volume":"22","author":"QM Wang","year":"2004","unstructured":"Wang, Q. M. et al. Improved immunogenicity of a tuberculosis DNA vaccine encoding ESAT6 by DNA priming and protein boosting. Vaccine 22, 3622\u20133627 (2004).","journal-title":"Vaccine"},{"key":"21369_CR50","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1056\/NEJM199701093360202","volume":"336","author":"JA Stoute","year":"1997","unstructured":"Stoute, J. A. et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med 336, 86\u201391 (1997).","journal-title":"N Engl J Med"},{"key":"21369_CR51","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1086\/318534","volume":"183","author":"KE Kester","year":"2001","unstructured":"Kester, K. E. et al. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J Infect Dis 183, 640\u2013647 (2001).","journal-title":"J Infect Dis"},{"key":"21369_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/srep46621","volume":"7","author":"KA Collins","year":"2017","unstructured":"Collins, K. A., Snaith, R., Cottingham, M. G., Gilbert, S. C. & Hill, A. V. S. Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine. Scientific reports 7, 46621 (2017).","journal-title":"Scientific reports"},{"key":"21369_CR53","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/j.1365-2583.2012.01168.x","volume":"22","author":"M Sumitani","year":"2013","unstructured":"Sumitani, M. et al. Reduction of malaria transmission by transgenic mosquitoes expressing an antisporozoite antibody in their salivary glands. Insect Mol Biol 22, 41\u201351 (2013).","journal-title":"Insect Mol Biol"},{"key":"21369_CR54","doi-asserted-by":"crossref","unstructured":"Triller, G. et al. Natural parasite exposure induces protective human anti-malarial antibodies. Immunity 47, 1197\u20131209, e1110 (2017).","DOI":"10.1016\/j.immuni.2017.11.007"},{"key":"21369_CR55","doi-asserted-by":"publisher","first-page":"e115161","DOI":"10.1371\/journal.pone.0115161","volume":"9","author":"E de Barra","year":"2014","unstructured":"de Barra, E. et al. A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS. PLoS One 9, e115161 (2014).","journal-title":"PLoS One"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-21369-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-21369-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-21369-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T22:01:40Z","timestamp":1671573700000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-21369-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,1]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["21369"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-21369-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,1]]},"assertion":[{"value":"13 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have read the journal\u2019s policy and declare the following conflicts of interest: S.Y. and A.H. are named inventors on filed patents related to immunization with the B.D.E.S. (WO\/2007\/091624) and ChAd63 (WO\/2008\/122769) anti-malaria vaccines, respectively. Neither of these products has been commercialized. None of the authors have undertaken any consultancies relevant to this study. These conflicts of interest do not alter the authors\u2019 adherence to all the policies of <i>Scientific Reports<\/i> on sharing data and materials, as detailed online in the guide for authors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"3896"}}